Overcoming tumor hypoxia: factors influencing the efficacy of the hypoxia-activated prodrug CP-506

Research output: ThesisDoctoral ThesisInternal

516 Downloads (Pure)

Abstract

Hypoxia – defined as a low level of oxygen – is a common characteristic of the majority of solid tumors and contributes to disease progression and resistance to conventional therapies. Overcoming tumor hypoxia is therefore a promising strategy to improve cancer treatment. Hypoxia-activated prodrugs (HAP) are therapeutic agents that are activated only in hypoxic regions of the tumor and not in healthy tissues. This thesis investigated a novel HAP, called CP-506. CP-506 was found to have potent antitumor effects in a broad range of cancer types, both as a monotherapeutic agent, but even more so in combination with radiotherapy and immunotherapy. In addition, the degree of hypoxia and genetic status of the tumor were strong determinants of the tumoral response to CP-506. Based on findings in this thesis, CP-506 will be tested for the first time in humans in a phase 1/2a clinical trial soon.
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
  • Maastricht University
Supervisors/Advisors
  • Lambin, Philippe, Supervisor
  • Dubois, Ludwig, Supervisor
  • Yaromina, Ala, Co-Supervisor
Award date2 Feb 2023
Place of PublicationMaastricht
Publisher
Print ISBNs9789083303284
DOIs
Publication statusPublished - 2023

Keywords

  • cancer
  • hypoxia
  • hypoxia-activated prodrugs
  • precision medicine

Fingerprint

Dive into the research topics of 'Overcoming tumor hypoxia: factors influencing the efficacy of the hypoxia-activated prodrug CP-506'. Together they form a unique fingerprint.

Cite this